Clinical Trial Update: 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the PET imaging agent 68Ga-DOTATOC for somatostatin receptor–positive neuroendocrine tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor

Drugs mentioned

• 68Ga-DOTATOC (DOTATOC)

Snippet

Sponsor: Lale Kostakoglu | Conditions: Neuroendocrine Tumors, Carcinoid Tumors | Phase 1 | Status: TERMINATED